Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 9Capecitabine 9Paclitaxel 7Fluorouracil 7pembrolizumab 6Leucovorin 6Cisplatin 5zolbetuximab 4Docetaxel 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Nivolumab 3Irinotecan 3Gemcitabine 3Albumin-Bound Paclitaxel 3fludarabine 2darolutamide 2atezolizumab 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Pemetrexed 2Cyclophosphamide 2Carboplatin 2130-nm albumin-bound paclitaxel 2vistusertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Prodrugs × 90 days × Clear all
NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡